ORM2 and rheumatoid arthritis: Second, since there is no commercially available neutralizing anti-ORM2 Ab, we could not determine whether targeting ORM2 is of therapeutic benefit and failed to determine how important the ORM2-driven inflammatory network is in RA joint pathology, where many other proinflammatory molecules, including cytokines, are involved.